Signe Lykke Nielsen

Signe Lykke Nielsen

bioanalyst

  • Molecular and Cellular Pharmacology

    Jagtvej 160, 2100 København Ø

    Phone: +45 35 33 10 37Mobile: +45 23 26 76 63

Publication year:
  1. 2016
  2. Published

    A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification

    Tarpgaard, L. S., Qvortrup, C., Nygård, S. B., Nielsen, Signe Lykke, Andersen, D. R., Jensen, N. F., Stenvang, Jan, Detlefsen, S., Brünner, Nils & Pfeiffer, P., 2016, In : B M C Cancer. 16, 5 p., 91.

    Research output: Contribution to journalJournal article

  3. Published

    DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer

    Nygård, S. B., Vainer, B., Nielsen, Signe Lykke, Bosman, F. T., Tejpar, S., Roth, A., Delorenzi, M., Brünner, Nils & Budinska, E., 2016, In : Clinical Cancer Research. 22, 7, p. 1621-1631

    Research output: Contribution to journalJournal article

  4. Published

    Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

    Jandu, H., Aluzaité, K., Fogh, L., Thrane, S. W., Noer, Julie Boertmann, Proszek, J., Nguyen Do, K., Hansen, S. N., Damsgaard-Hansen, B., Nielsen, Signe Lykke, Stougaard, M., Knudsen, B. R., Moreira, José, Hamerlik, P., Gajjar, M., Smid, M., Martens, J., Foekens, J., Pommier, Y., Brünner, Nils, Rasmussen, A. S. & Stenvang, Jan, 22 Jan 2016, In : B M C Cancer. 16, 13 p., 34.

    Research output: Contribution to journalJournal article

ID: 37447272